Pharmacological management of rare coagulation factor deficiencies besides hemophilia

References

• Dorgalaleh A, Tabibian S, Soori S, et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology. 2017;22(4):224–230.
   PubMed Web of Science ®Google Scholar
• Girolami A, Cosi E, Ferrari S, et al. Prothrombin: another clotting factor after FV that is involved both in bleeding and thrombosis. Clin Appl Thromb Hemost. 2018;24(6):845–849.
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016;30(6):461–475.
   PubMed Web of Science ®Google Scholar
• Casini A, Moerloose P. Factor concentrates for rare congenital coagulation disorders: where are we now? Expert Opin Orphan Drugs. 2016;4(1):49–62.
   Web of Science ®Google Scholar
• Iorio A, McEneny-King A, Keepanasseril A, et al. What is the role for population pharmacokinetics in hemophilia? Int J Pharmacokinet. 2017;2:125–136.
   Google Scholar
• Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013;39:684–692.
   PubMed Web of Science ®Google Scholar
• Bérubé C. Factor XI (eleven) deficiency. In: Leung LLK, Tirnauer JS, editors. UpToDate. Waltham, MA: UpToDate Inc; 2019.
   Google Scholar
• Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370(9585):439–448.
   PubMed Web of Science ®Google Scholar
• Korte W, Poon MC, Iorio A, et al. Thrombosis in Inherited Fibrinogen Disorders. Transfus Med Hemother. 2017;44(2):70–76.
   PubMed Web of Science ®Google Scholar
• Djambas Khayat C, El Khorassani M, Lambert T, et al. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency. J Thromb Haemost. 2019;17(4):635–644.
   Google Scholar
• Negrier C, Rothschild C, Borg JY, et al. Post-authorization safety study of Clottafact, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study. Vox Sang. 2016;111(4):383–390.
   PubMed Web of Science ®Google Scholar
• Stroka D, Keogh A, Vu D, et al. In vitro rescue of FGA deletion by lentiviral transduction of an afibrinogenemic patient’s hepatocytes. J Throm Haemos. 2014;12(11):1874–1879.
   Google Scholar
• Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005;32(3):247–253.
   PubMed Web of Science ®Google Scholar
• De Mattia D, Regina G, Giordano P, et al. Association of congenital afibrinogenemia and K-dependent protein C deficiency – a case report. Angiology. 1993;44(9):745–749.
   PubMed Web of Science ®Google Scholar
• Solomon C, Gröner A, Jain Y, et al. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost. 2015;113(4):759–771.
   PubMed Web of Science ®Google Scholar
• Bornikova L, Peyvandi F, Allen G, et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Throm Haemos. 2011;9(9):1687–1704.
   Google Scholar
• Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014;167(3):304–326.
   PubMed Web of Science ®Google Scholar
• Valiton V, Hugon-Rodin J, Fontana P, et al. Obstetrical and postpartum complications in women with hereditary fibrinogen disorders: a systematic literature review. Haemophilia. 2019;25(5):747–754.
   PubMed Web of Science ®Google Scholar
• Patil R, Mukaddam A, Ghosh K, et al. Management of pregnancy in dysfibrinogenemia cases: A dilemma. Blood Coagul Fibrinolysis. 2017;28(1):91–93.
   PubMed Web of Science ®Google Scholar
• Blondon M, Casini A, Hoppe KK, et al. Risks of venous thromboembolism after cesarean sections: a meta-analysis. Chest. 2016;150(3):572–596.
   PubMed Web of Science ®Google Scholar
• Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia. 2011;17(Suppl 1):20–30.
   PubMed Web of Science ®Google Scholar
• Oda T, Itoh H, Kawai K, et al. Three successful deliveries involving a woman with congenital afibrinogenaemia—Conventional fibrinogen concentrate infusion vs. ‘as required’ fibrinogen concentrate infusion based on changes in fibrinogen clearance. Haemophilia. 2016;22(5):e478–81.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kanayama N, Tokunaga N, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol. 2000;109(2):364–366.
   PubMed Web of Science ®Google Scholar
• Cortet M, Deneux-Tharaux C, Dupont C. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial, observational safety study of clottafact® fibrinogen concentrate: real-world data in Mexico. Br J Anaesth. 2012;108(6):984–989.
   PubMed Web of Science ®Google Scholar
• De Vries A, Rosenberg T, Kochwa S, et al. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med. 1961;30(3):486–494.
   PubMed Web of Science ®Google Scholar
• Schuepbach RA, Meili EO, Schneider E, et al. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost. 2004;91(5):1044–1046.
   PubMed Web of Science ®Google Scholar
• Lebreton A, Casini A, Alhayek R, et al. Successful pregnancy under fibrinogen substitution in a woman with congenital afibrinogenaemia complicated by a postpartum venous thrombosis. Haemophilia. 2015;21(1):e108–10.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8(3):149–154.
   PubMed Web of Science ®Google Scholar
• Mathias M, Pollard D, Riddell A. Prophylaxis in severe prothrombin deficiency. Br J Haematol. 2011;152(2):243–244.
   PubMed Web of Science ®Google Scholar
• Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost. 2013;39:596–606.
   PubMed Web of Science ®Google Scholar
• Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia. 2001;7(suppl 1):16–22.
   PubMedGoogle Scholar
• Pavord S, Rayment R, Madan B, et al. on behalf of the Royal college of obstetricians and gynaecologists. Management of inherited bleeding disorders in pregnancy. Green-top guideline no. 71. BJOG. 2017;124:e193–e263.
   PubMedGoogle Scholar
• Djordjevic V, Kovac M, Miljic P, et al. A novel prothrombin mutation in two families with prominent thrombophilia–the first cases of antithrombin resistance in a Caucasian population. J Throm Haemos. 2013;11(10):1936–1939.
   Google Scholar
• Drzymalski DM, Elsayes AH, Ward KR, et al. Platelet transfusion as treatment for factor V deficiency in the parturient: a case report. Transfusion. 2019;59(7):2234–2237.
   PubMed Web of Science ®Google Scholar
• Mingot-Castellano ME, Pérez-Núñez J, Baeza-Montañez L. Hip replacement surgery in 14-year-old girl with Factor V deficiency: haemostatic treatment and thromboprophylaxis. Case Rep Hematol. 2016;2016.
   Web of Science ®Google Scholar
• Gonzalez‐Boullosa R, Ocampo‐Martinez R, Alarcon‐Martin M, et al. The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency. Haemophilia. 2005;11(2):167–170.
   PubMed Web of Science ®Google Scholar
• Bulato C, Novembrino C, Anzoletti MB, et al. “In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. Haemophilia. 2018;24(4):648–656.
   PubMed Web of Science ®Google Scholar
• Frotscher B, Toussaint‐Hacquard M, Fouyssac F, et al. Severe factor V deficiency in two brothers with different clinical presentations. Haemophilia. 2012;18(5):e383–5.
   PubMed Web of Science ®Google Scholar
• Safarpour MM, Haghpanah S, Meshksar A, et al. Phenotype report on patients with congenital Factor V deficiency in Southern Iran: recent ten years’ experience. Turk J Haematol. 2017;34(3):250–253.
   PubMed Web of Science ®Google Scholar
• Salooja N, Martin P, Khair K, et al. Severe factor V deficiency and neonatal intracranial haemorrhage: a case report. Haemophilia. 2000;6(1):44–46.
   PubMed Web of Science ®Google Scholar
• Totan M, Albayrak D. Intracranial haemorrhage due to factor V deficiency. Acta Paediatr. 1999;88(3):342–343.
   PubMed Web of Science ®Google Scholar
• Sanklecha MU, Sundaresan S, Charde V. Factor V deficiency: A subtle presentation. Indian J Pediatr. 2014;81(3):283–284.
   Google Scholar
• Tabibian S, Shiravand Y, Shams M et al. editors, A comprehensive overview of coagulation factor V and congenital factor V deficiency Semin Thromb Hemost 2019 455523–543
   PubMed Web of Science ®Google Scholar
• Girolami A, Scandellari R, Lombardi A, et al. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia. 2005;11(1):26–30.
   PubMed Web of Science ®Google Scholar
• Stalnaker M, Esquivel P. Managing menorrhagia in a familial case of factor V deficiency. J Pediatr Adol Gynec. 2015;28(1):e9–12.
   PubMedGoogle Scholar
• Rouzi A, Qari M, Ardawi M. The use of fresh frozen plasma for reproduction in severe factor V deficiency. Clin Exp Obstet Gynecol. 2015;42(3):384–385.
   PubMed Web of Science ®Google Scholar
• Passarelli PC, De Angelis P, Pasquantonio G, et al. Management of single uncomplicated dental extractions and postoperative bleeding evaluation in patients with Factor V deficiency: a local antihemorrhagic approach. J Oral Maxillofac Surg. 2018;76(11):2280–2283.
   PubMed Web of Science ®Google Scholar
• Rideau C, Gaertner E, Blay M, et al. Successful management of fresh‐frozen plasma transfusion therapy based upon clinical symptoms for total knee arthroplasty in a patient with severe factor V deficiency. Haemophilia. 2010;16(2):381–383.
   PubMed Web of Science ®Google Scholar
• Ang AL, Kuperan P, Ng CH, et al. Acquired factor V inhibitor. Thromb Haemost. 2009;101(5):852–859. doi:10.1160/TH08-11-0767
   PubMed Web of Science ®Google Scholar
• Ardillon L, Lefrancois A, Graveleau J, et al. Management of bleeding in severe factor V deficiency with a factor V inhibitor. Vox Sang. 2014;107(1):97–99.
   PubMed Web of Science ®Google Scholar
• Divanon F, Hecquard C, Borel‐Derlon A. Experience with use of recombinant activated factor VII. J Clin Pharm Ther. 2002;27(2):133–138.
   PubMed Web of Science ®Google Scholar
• de Raucourt E, Barbier C, Sinda P, et al. High‐dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol. 2003;74(3):187–190.
   PubMed Web of Science ®Google Scholar
• Lee WS, Chong LA, Begum S, et al. Factor V inhibitor in neonatal intracranial hemorrhage secondary to severe congenital factor V deficiency. J Pediatr Hematol Oncol. 2001;23(4):244–246.
   PubMed Web of Science ®Google Scholar
• Mansouritorghabeh H, Shirdel A. Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial. J Throm Haemos. 2016;14(2):336–339.
   Google Scholar
• Shao Y, Wu W, Xu G, et al. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII. Blood, Blood. 2019;134(20):1745–1754.
   PubMed Web of Science ®Google Scholar
• Spiliopoulos D, Kadir RA. Congenital factor V and VIII deficiency in women: a systematic review of literature and report of two new cases. Blood Coagul Fibrin. 2016;27(3):237–241.
   PubMed Web of Science ®Google Scholar
• Howard C, Lipe B. Combined deficiency of factor V and factor VIII: management during cardiothoracic surgery. Blood Coagul Fibrin. 2017;28(3):267–268.
   PubMed Web of Science ®Google Scholar
• Brown L, Tilzer L, Plapp F. Factor V and VIII deficiency treated with therapeutic plasma exchange prior to redo mitral valve replacement. J Clin Apher. 2017;32(3):196–199.
   PubMed Web of Science ®Google Scholar
• Mansouri Torghabeh H, Pourfathollah AA, Mahmoodian Shooshtari M, et al. Factor V and VIII inhibitor in patients with combined factor V and VIII deficiency. MJIRI. 2005;18(4):309–313.
   Google Scholar
• Eshghi P, Tara SZ, Baghaipour MR, et al. Inhibitors against rFVIIa in patients with severe congenital FVII deficiency: A case series. Haemophilia. 2019;25(5):e345.
   PubMed Web of Science ®Google Scholar
• Shams M, Dorgalaleh A, Safarian N, et al. Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients. Blood Coagul Fibrin. 2019;30(1):24–28.
   PubMed Web of Science ®Google Scholar
• Bywood P, Newton S, Mundy L, et al. Evidence-based clinical practice guidelines for the use of recombinant and plasma-derived FVIII and FIX products:. National Blood Authority; 2006.
   Google Scholar
• Herrmann F, Wulff K, Auerswald G, et al. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia. 2009;15(1):267–280.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Giansily-Blaizot M, Dolce A, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013;98(4):538–544.
   PubMed Web of Science ®Google Scholar
• Farah RA, Hamod D, Melick N, et al. Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency. J Throm Haemost. 2007;5(2):433–434.
   PubMed Web of Science ®Google Scholar
• Mariani G, Napolitano M, Dolce A, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost. 2013;109(2):238–247.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Di Minno MND, Batorova A, et al. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. Haemophilia. 2016;22(5):752–759.
   PubMed Web of Science ®Google Scholar
• Batorova A, van Galen K, von Mackensen S. et al. Gynaecological issues in women with bleeding disorders: CSL Behring symposium. J Haemophilia Pract. 2019;6(2):28–38.
   Google Scholar
• Mariani G, Dolce A, Marchetti G, et al. Clinical picture and management of congenital factor VII deficiency. Haemophilia. 2004;10(Suppl 4):180–183.
   PubMedGoogle Scholar
• Tran H, Tjønnfjord G, Paus A, et al. rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemophilia. 2011;17(5):764–770.
   PubMed Web of Science ®Google Scholar
• Mariani G, Dolce A, Batorova A, et al. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation–the surgical STER. Br J Haematol. 2011;152(3):340–346.
   PubMed Web of Science ®Google Scholar
• Tokgoz H, Caliskan U, Lavigne‐Lissalde G, et al. Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII. Haemophilia. 2012;18(1):e25–e27.
   Google Scholar
• Marty S, Barro C, Chatelain B, et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008;14(3):564–570.
   PubMed Web of Science ®Google Scholar
• Paulus E, Komperda K, Park G, et al. Anticoagulation therapy considerations in factor VII deficiency. Drug Saf Case Rep. 2016;3(1):8.
   PubMedGoogle Scholar
• Baltodano LE, Mungall DR, Watson DD. Management of a patient with atrial fibrillation and factor VII deficiency. Ann Pharmacother. 1998;32(11):1251–1252.
   PubMed Web of Science ®Google Scholar
• Liesner R, Akanezi C, Norton M, et al. Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate. Haemophilia. 2018;24(6):941–949.
   PubMed Web of Science ®Google Scholar
• Kulkarni R, James AH, Norton M, et al. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency. J Throm Haemos. 2018;16(5):849–857.
   Google Scholar
• Spiliopoulos D, Kadir RA. Congenital Factor X deficiency in women: a systematic review of the literature. Haemophilia. 2019;25(2):195–204.
   PubMed Web of Science ®Google Scholar
• Martín-Salces A-RMT, Rodríguez-Merchán EC, Jiménez-Yuste V. Femur fracture in a woman with severe factor X deficiency—an experience using factor X concentrate in surgery. Haemophilia. 2013;6(19):e369–70.
   Google Scholar
• Bakhtiari K, Meijers JCM. In vitro evaluation of factor IX as novel treatment for factor XI deficiency. Blood. 2019;134(6):573–575.
   PubMed Web of Science ®Google Scholar
• Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 1985;65(3):719–724.
   PubMed Web of Science ®Google Scholar
• Brenner B, Laor A, Lupo H, et al. Bleeding predictors in factor-XIdeficient patients. Blood Coagul Fibrin. 1997;8(8):511–515.
   PubMed Web of Science ®Google Scholar
• Dai L, Rangarajan S, Mitchell M. Three dominant-negative mutations in factor XI-deficient patients. Haemophilia. 2011;17(5):e919–22.
   PubMed Web of Science ®Google Scholar
• Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol. 2016;9(7):629–637.
   PubMed Web of Science ®Google Scholar
• Verghese L, Tingi E, Thachil J, et al. Management of parturients with factor XI deficiency-10 year case series and review of literature. Eur J Obstet Gynecol Reprod Biol. 2017;215:85–92.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol. 1988;69(4):521–528.
   PubMed Web of Science ®Google Scholar
• Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost. 2009;102(9):487–492.
   PubMedGoogle Scholar
• Salomon S, SteinbergIlia DM, Tamarin T. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrin. 2005;16(1):37–41.
   PubMed Web of Science ®Google Scholar
• Setty S, Reddell A, England A, et al. The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency. Haemophilia. 2011;17(6):906–909.
   PubMed Web of Science ®Google Scholar
• Riddell A, Abdul-Kadir R, Pollard D, et al. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost. 2011;106(9):521–527.
   PubMedGoogle Scholar
• Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008;14(6):1183–1189.
   PubMed Web of Science ®Google Scholar
• Pike GA, Cumming C, Hay P, et al. Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency. Blood. 2015;126(3):397–405.
   PubMed Web of Science ®Google Scholar
• Salomon O, Budnik I, Avishai E, et al. Single low dose of rFVIIa combined with Antifibrinolytic agent is a simple and safe treatment for Factor XI-Deficient patients undergoing surgery. Thromb Haemost. 2019;119(12):1927–1932.
   PubMed Web of Science ®Google Scholar
• Solomon C, Korte W, Fries D, et al. Safety of factor XIII concentrate: analysis of more than 20 years of pharmacovigilance data. Transfus Med Hemother. 2016;43(5):365–373.
   PubMed Web of Science ®Google Scholar
• Inbal A, Oldenburg J, Carcao M, et al. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012;119(22):5111–5117.
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Naderi M, Hosseini MS, et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41(3):323–329.
   PubMed Web of Science ®Google Scholar
• Janbain M, Nugent DJ, Powell JS, et al. Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. Transfusion. 2015;55(1):45–50.
   PubMed Web of Science ®Google Scholar
• Hosseini MS, Shams M, Dorgalaleh A, et al. Multiple coagulation factor deficiency. In: Dorgalaleh A, editor. Congenital Bleeding Disorders:. Springer; 2018. p. 219–238.
   Google Scholar
• Bhattacharyya J, Dutta P, Mishra P, et al. Congenital vitamin K-dependent coagulation factor deficiency: a case report. Blood Coagul Fibrinol. 2005;16(7):525–527.
   PubMed Web of Science ®Google Scholar
• Rost S, Fregin A, Koch D, et al. Compound heterozygous mutations in the γ‐glutamyl carboxylase gene cause combined deficiency of all vitamin K‐dependent blood coagulation factors. Br J Haematol. 2004;126(4):546–549.
   PubMed Web of Science ®Google Scholar
• Mousallem M, SpronK HM, Sacy R, et al. Congenital combined deficiencies of all vitamin K-dependent coagulation factors. Thromb Haemost. 2001;86(11):1334–1336. doi:10.1055/s-0037-1616072
   PubMedGoogle Scholar
• Darghouth D, Hallgren KW, Shtofman RL, et al. Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K–dependent coagulation factor deficiency. Blood. 2006;108(6):1925–1931.
   PubMed Web of Science ®Google Scholar
• McMahon MJ, James AH. Combined deficiency of factors II, VII, IX, and X (Borgschulte-Grigsby deficiency) in pregnancy. Obstet Gynecol. 2001;97(5):808–809.
   PubMed Web of Science ®Google Scholar
• Lapecorella M, Napolitano M, Bernardi F, et al. Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors. Clin Appl Thromb/Hems. 2010;16(2):221–223.
   PubMed Web of Science ®Google Scholar